Trials show weight-loss jab could relieve knee osteoarthritis pain
Phase 3 studies find high-dose retatrutide recipients lost up to 25% of their body weight on average, while around two-thirds reported at least a 50% reduction in knee pain.
Two Phase 3 clinical trials involving more than 1,000 adults found that people prescribed high doses of Eli Lilly's experimental GLP-1-based drug retatrutide lost, on average, up to 25% of their body weight, while around two-thirds receiving the active injectable reported at least a 50% reduction in knee osteoarthritis pain, strengthening the case for the drug to gain FDA approval for weight loss and knee osteoarthritis relief.